

Macular Degeneration Guideline Committee – development

Date: Thursday 5th January 2017

Location: NICE offices, Manchester

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for all items
Katy Barnard (KB)	Present for all items
Nick Beare (NB)	Present for all items
Cathie Burke (CB)	Present for all items
Andy Charley (AC)	Present for all items
Jennifer Evans (JE)	Present for all items
Alexander Foss (AF)	Present for all items
Carol McCletchie (CM)	Present from item 2
Mary-Ann Sherratt (MS)	Present for all items
Elizabeth Wick (EW)	Present for all items
Cathy Yelf (CY)	Present until the end of item 4

In attendance:	
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present for all items
Sue Ellerby (SE) ICG – Clinical Advisor	Present for all items
Jamie Elvidge ICG – Technical Analyst (HE)	Present for all items
Andrew Gyton (AG) Commissioning Manager	Present for all items
Lesley Hayes	Present for all items

Macular Degeneration Guideline Committee 12 minutes

NICE – Business Analyst	
Vonda Murray (VM) ICG – Project Manager	Present for all items
Dave Nicholls (DN) NICE – Information Specialist	Present for all items
Gabriel Rogers (GR) ICG – Technical Advisor (HE)	Present for all items
Yingying Wang (YW) ICG – Technical Analyst	Present for all items

Observers:	
Judith Hughes PhD student	Present until the end of item 3
Rachael Kettle Technical Lead	Present until the end of item 2
Albany Meikle Assistant Technical Analyst	Present until the end of item 2

Apologies:	
Mary Freeman	Committee member
Ellen Rule	Committee member
Sue Spiers	NICE – ICG, Associate Director

1. Introductions, apologies, minutes, DOI and objectives for the meeting

Macular Degeneration Guideline Committee 12 minutes

The Chair welcomed the Committee members, attendees and observers to the 12th meeting on age-related macular degeneration (AMD). The committee members, attendees and observers introduced themselves.

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
Elizabeth Wick	Interview for the Mirror newspaper, about her experience of living with AMD. No payment received	Declare and participate

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GComm 11; 6th and 7th December 2016. The minutes were agreed to be an accurate record.

The Chair provided an overview of the objectives for the day highlighting the information that would be discussed.

Item 2

RQ10) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity better than 6/12?

RQ12) What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ14) What factors indicate that treatment for neovascular AMD should be stopped?

RQ18) What is the effectiveness of different frequencies of administration

for anti-VEGF regimens for the treatment of neovascular AMD?

RQ25) What is the effectiveness of treatment of neovascular AMD in people presenting with visual acuity worse than 6/96?

- Presentation of the original health economic model

GR provided an overview of how the information would be presented for the anti-VEFG questions. YW presented a summary of the clinical evidence on the effectiveness of different anti-angiogenic and different frequencies of administration of antiangiogenic therapies for the treatment of neovascular AMD. JE presented a summary the published health economic evidence for all of the above review questions, followed by the original economic model developed to provide evidence for all of the above review questions.

Item 3

RQ10, RQ12, RQ14, RQ18 & RQ25 continued

- Presentation of the original health economic model
- Draft recommendations

JE continued with presenting the health economic model for the above questions.

LUNCH

Item 4

RQ10, RQ12, RQ14, RQ18 & RQ25 continued

- Draft recommendations

The committee discussed the evidence and made recommendations.

Item 5

RQ24) How soon should people with neovascular AMD be diagnosed and treated after becoming symptomatic?

- Review draft recommendation

The committee agreed due to time constraints to defer the item to GComm13.

Macular Degeneration Guideline Committee 12 minutes

Item 6 Any other business
--

Item 7 Summary and next steps
--

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting were confirmed.
--

Date of next meeting: GComm - Monday 13th February 2017

Location of next meeting: NICE offices, London